Published in Lancet Oncol on August 06, 2010
Prediction of Response to Neoadjuvant Therapy in Rectal Cancer (PRENT-LARC) | NCT02439086
Patients With Rectal Cancer: a "Wait-and-see" Approach | NCT03001362
Complete Pathologic Response Rectal Cancers (CORSiCA) | NCT03351959
Microbiome and Rectal Cancer | NCT04223102
DETECT: Target Volume for Rectal Endoluminal Radiation Boosting (DETECT) | NCT04927897
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol (2012) 2.22
Assessment of Clinical Complete Response After Chemoradiation for Rectal Cancer with Digital Rectal Examination, Endoscopy, and MRI: Selection for Organ-Saving Treatment. Ann Surg Oncol (2015) 1.69
Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg (2015) 1.69
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol (2015) 1.67
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol (2011) 1.49
Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging. Tech Coloproctol (2014) 1.45
Is there a role for adjuvant chemotherapy in pathological complete response rectal cancer tumors following neoadjuvant chemoradiotherapy? J Cancer Res Clin Oncol (2014) 1.43
Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg (2011) 1.43
Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol (2011) 1.38
Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer. Ann Surg (2011) 1.24
Oncological superiority of extralevator abdominoperineal resection over conventional abdominoperineal resection: a meta-analysis. Int J Colorectal Dis (2014) 1.10
Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies. Ann Surg Oncol (2011) 1.08
Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci (2012) 1.07
Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol (2013) 1.04
Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys (2012) 1.04
Predicting the response to preoperative radiation or chemoradiation by a microarray analysis of the gene expression profiles in rectal cancer. Surg Today (2012) 1.02
Neoadjuvant chemotherapy first, followed by chemoradiation and then surgery, in the management of locally advanced rectal cancer. J Natl Compr Canc Netw (2014) 1.01
Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer. Dis Colon Rectum (2013) 1.01
Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. Br J Cancer (2011) 1.01
Current approaches and challenges for monitoring treatment response in colon and rectal cancer. J Cancer (2014) 1.00
Can we predict pathologic complete response before surgery for locally advanced rectal cancer treated with preoperative chemoradiation therapy? Int J Colorectal Dis (2011) 1.00
Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy. Dis Colon Rectum (2013) 0.98
Metformin use and improved response to therapy in rectal cancer. Cancer Med (2013) 0.97
Clinicopathologic Comparison of High-Dose-Rate Endorectal Brachytherapy versus Conventional Chemoradiotherapy in the Neoadjuvant Setting for Resectable Stages II and III Low Rectal Cancer. Int J Surg Oncol (2012) 0.96
Advances and challenges in treatment of locally advanced rectal cancer. J Clin Oncol (2015) 0.96
Locally advanced rectal cancer: is diffusion weighted MRI helpful for the identification of complete responders (ypT0N0) after neoadjuvant chemoradiation therapy? Eur Radiol (2013) 0.95
Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. Cancer (2014) 0.92
The CARTS study: Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery. BMC Surg (2011) 0.92
Controversies in the pathological assessment of colorectal cancer. World J Gastroenterol (2014) 0.92
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol (2011) 0.92
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol (2013) 0.91
Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol (2016) 0.91
Personalized surgical management of colorectal cancer in elderly population. World J Gastroenterol (2014) 0.91
Interval to surgery after neoadjuvant treatment for colorectal cancer. World J Gastroenterol (2014) 0.90
Diffusion-weighted MRI in locally advanced rectal cancer : pathological response prediction after neo-adjuvant radiochemotherapy. Strahlenther Onkol (2012) 0.90
Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol Biol Phys (2014) 0.89
T2 weighted signal intensity evolution may predict pathological complete response after treatment for rectal cancer. Eur Radiol (2012) 0.89
Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target. Br J Cancer (2011) 0.89
Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. BMC Cancer (2015) 0.88
Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. Cancer (2012) 0.88
Association of life course socioeconomic disadvantage with future problem drinking and heavy drinking: gender differentials in the west of Scotland. Int J Public Health (2011) 0.88
Neoadjuvant therapy followed by local excision and two-stage total mesorectal excision: a new strategy for sphincter preservation in locally advanced ultra-low rectal cancer. Gastroenterol Rep (Oxf) (2014) 0.88
Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol (2012) 0.88
Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome. Surg Endosc (2013) 0.88
Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. J Am Coll Surg (2011) 0.87
Early prediction of pathological response in locally advanced rectal cancer based on sequential 18F-FDG PET. Acta Oncol (2012) 0.87
Down-staging following neoadjuvant chemo-radiotherapy for locally advanced rectal cancer: Does timing of surgery really matter? Indian J Med Paediatr Oncol (2014) 0.87
Prognostic value of mandard and dworak tumor regression grading in rectal cancer: study of a single tertiary center. ISRN Surg (2014) 0.87
Efficacy and Safety of Low-Dose-Rate Endorectal Brachytherapy as a Boost to Neoadjuvant Chemoradiation in the Treatment of Locally Advanced Distal Rectal Cancer: A Phase-II Clinical Trial. Ann Coloproctol (2015) 0.87
A patient with cholangiocarcinoma demonstrating pathologic complete response to chemotherapy: exploring the role of neoadjuvant therapy in biliary tract cancer. J Gastrointest Oncol (2014) 0.87
Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients. Int J Cancer (2014) 0.86
Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers. World J Gastroenterol (2013) 0.86
Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial. Oncotarget (2015) 0.86
Pathological complete response: still a relevant endpoint in rectal cancer? Lancet Oncol (2010) 0.86
Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision. Int J Colorectal Dis (2015) 0.86
Obesity was associated with a decreased postoperative recurrence of rectal cancer in a Japanese population. Surg Today (2014) 0.85
Mucinous adenocarcinoma of the rectum: a poor candidate for neo-adjuvant chemoradiation? J Gastrointest Oncol (2014) 0.85
An update on preoperative radiotherapy for locally advanced rectal cancer. J Korean Soc Coloproctol (2012) 0.84
Pretreatment high-resolution rectal MRI and treatment response to neoadjuvant chemoradiation. Dis Colon Rectum (2012) 0.84
High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer. Radiat Oncol (2015) 0.84
Nomogram to predict ypN status after chemoradiation in patients with locally advanced rectal cancer. Br J Cancer (2014) 0.83
Chromosomal copy number alterations are associated with persistent lymph node metastasis after chemoradiation in locally advanced rectal cancer. Dis Colon Rectum (2012) 0.83
Outcome of Local Excision Following Preoperative Chemoradiotherapy for Clinically T2 Distal Rectal Cancer: A Multicenter Retrospective Study (KROG 12-06). Cancer Res Treat (2014) 0.83
Predictive factors of the response of rectal cancer to neoadjuvant radiochemotherapy. Cancers (Basel) (2011) 0.83
Risk factors for adverse outcome in low rectal cancer. World J Gastroenterol (2012) 0.83
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). BMC Cancer (2014) 0.83
Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. Int J Radiat Oncol Biol Phys (2013) 0.82
Simple measurements on diffusion-weighted MR imaging for assessment of complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol (2014) 0.82
Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer? Front Oncol (2014) 0.82
Extramural depth of rectal cancer tumor invasion at thin-section MRI: predicting treatment response to neoadjuvant chemoradiation. Oncotarget (2015) 0.81
Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks. Int J Mol Sci (2014) 0.81
Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer. Cancer Res Treat (2015) 0.81
Prognostic significance of pathological response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Int J Clin Oncol (2015) 0.80
PET/CT with Fluorodeoxyglucose During Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Ecancermedicalscience (2016) 0.80
Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0. Int J Colorectal Dis (2014) 0.80
Watch and wait approach to rectal cancer: A review. World J Gastrointest Surg (2015) 0.80
Multidisciplinary treatment of rectal cancer in 2014: where are we going? World J Gastroenterol (2014) 0.80
MRI for Assessing Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer Using DCE-MR and DW-MR Data Sets: A Preliminary Report. Biomed Res Int (2015) 0.80
An individualized conditional survival calculator for patients with rectal cancer. Dis Colon Rectum (2013) 0.80
Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer. World J Radiol (2015) 0.80
Predicting complete response: is there a role for non-operative management of rectal cancer? J Gastrointest Oncol (2015) 0.79
Identification of hypoxanthine and phosphoenolpyruvic Acid as serum markers of chemoradiotherapy response in locally advanced rectal cancer. Cancer Res Treat (2014) 0.79
Nomogram basing pre-treatment parameters predicting early response for locally advanced rectal cancer with neoadjuvant chemotherapy alone: a subgroup efficacy analysis of FOWARC study. Oncotarget (2016) 0.79
Tumor response assessment in locally advanced colon cancer after neoadjuvant chemotherapy. J Gastrointest Oncol (2014) 0.79
Predictors of Pathologic Complete Response in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation. Medicine (Baltimore) (2015) 0.79
Locally advanced rectal cancer: the importance of a multidisciplinary approach. World J Gastroenterol (2014) 0.79
Sphincter-sparing surgery in patients with low-lying rectal cancer: techniques, oncologic outcomes, and functional results. J Gastrointest Surg (2014) 0.79
Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer: a single center experience. Radiat Oncol J (2016) 0.79
Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy. Onco Targets Ther (2013) 0.79
IMP3 expression in biopsy specimens of colorectal cancer predicts lymph node metastasis and TNM stage. Int J Clin Exp Pathol (2015) 0.79
Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. World J Gastroenterol (2014) 0.79
Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal Cancer. Front Oncol (2015) 0.78
An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy. Therap Adv Gastroenterol (2016) 0.78
Clinical predictive factors of pathologic complete response in locally advanced rectal cancer. Oncotarget (2016) 0.78
Clinical parameters predicting pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Chin J Cancer (2015) 0.78
Neoadjuvant oral vs. infusional chemoradiotherapy on locally advanced rectal cancer: Prognostic factors. Rep Pract Oncol Radiother (2012) 0.78
Update on advances and controversy in rectal cancer treatment. Tech Coloproctol (2016) 0.78
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med (2004) 25.68
Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet (2005) 10.11
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet (2005) 6.99
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol (2012) 5.41
Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol (2013) 4.75
Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol (2012) 4.26
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol (2008) 3.45
A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer. Ann Surg (2014) 3.43
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol (2011) 3.43
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Definition and delineation of the clinical target volume for rectal cancer. Int J Radiat Oncol Biol Phys (2006) 2.92
Functional compromise reflected by sarcopenia, frailty, and nutritional depletion predicts adverse postoperative outcome after colorectal cancer surgery. Ann Surg (2015) 2.61
Local excision after preoperative chemoradiotherapy for rectal cancer: results of a multicenter phase II clinical trial. Dis Colon Rectum (2013) 2.52
Quality indicators in radiation oncology. Int J Radiat Oncol Biol Phys (2012) 2.48
Elective clinical target volumes for conformal therapy in anorectal cancer: a radiation therapy oncology group consensus panel contouring atlas. Int J Radiat Oncol Biol Phys (2008) 2.45
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer (2007) 2.40
Multidisciplinary team working in cancer: what is the evidence? BMJ (2010) 2.38
Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys (2008) 2.30
Duodenal toxicity after fractionated chemoradiation for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys (2012) 2.29
Evidence-based medicine: the time has come to set standards for staging. J Pathol (2010) 2.26
Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: results of study CAO/ARO/AIO-94. Int J Radiat Oncol Biol Phys (2006) 2.26
Predicting outcomes in radiation oncology--multifactorial decision support systems. Nat Rev Clin Oncol (2012) 2.23
Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol (2012) 2.22
The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 2.18
Rectal cancer: assessment of complete response to preoperative combined radiation therapy with chemotherapy--conventional MR volumetry versus diffusion-weighted MR imaging. Radiology (2011) 2.18
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol (2006) 2.10
Pathophysiology and management of radiation-induced xerostomia. J Support Oncol (2005) 2.09
The role of adjuvant radiation in endometrial cancer. Oncology (Williston Park) (2009) 2.07
Spinal injection therapy for low back pain. JAMA (2013) 2.05
Neoadjuvant chemoradiation in rectal cancer: time to start in a new direction. J Clin Oncol (2011) 2.05
Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw (2011) 2.03
Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck. Strahlenther Onkol (2015) 1.98
Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology (2005) 1.94
cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol (2008) 1.93
Radiation-induced lung injury. Semin Radiat Oncol (2003) 1.82
Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol (2009) 1.82
Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol (2006) 1.80
Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res (2005) 1.76
The Cassava Genome: Current Progress, Future Directions. Trop Plant Biol (2012) 1.75
Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys (2010) 1.73
A systematic review of resectability and survival after concurrent chemoradiation in primarily unresectable pancreatic cancer. Ann Surg Oncol (2009) 1.70
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys (2012) 1.70
Restaging locally advanced rectal cancer with MR imaging after chemoradiation therapy. Radiographics (2010) 1.67
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol (2010) 1.65
Low anterior resection syndrome and quality of life: an international multicenter study. Dis Colon Rectum (2014) 1.63
Systematic review of the use of a mesh to prevent parastomal hernia. World J Surg (2010) 1.62
T-cell responses to survivin in cancer patients undergoing radiation therapy. Clin Cancer Res (2008) 1.61
Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. Int J Radiat Oncol Biol Phys (2007) 1.61
High-resolution MR imaging for nodal staging in rectal cancer: are there any criteria in addition to the size? Eur J Radiol (2004) 1.61
'Rapid Learning health care in oncology' - an approach towards decision support systems enabling customised radiotherapy'. Radiother Oncol (2013) 1.60
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol (2009) 1.55
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
Radiochemotherapy after transurethral resection for high-risk T1 bladder cancer: an alternative to intravesical therapy or early cystectomy? J Clin Oncol (2006) 1.53
Characteristics of injection drug users who participate in drug dealing: implications for drug policy. J Psychoactive Drugs (2008) 1.53
Esophageal and esophagogastric junction cancers, version 1.2015. J Natl Compr Canc Netw (2015) 1.52
Didox (a novel ribonucleotide reductase inhibitor) overcomes Bcl-2 mediated radiation resistance in prostate cancer cell line PC-3. Cancer Biol Ther (2002) 1.51
Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2008) 1.50
The prognostic effect of clinical staging in pancreatic adenocarcinoma. Ann Surg Oncol (2005) 1.50
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol (2011) 1.49
Gastric cancer: apples will always be apples. J Clin Oncol (2012) 1.49
Rectal cancer. J Natl Compr Canc Netw (2012) 1.49
Par-4, a pro-apoptotic gene, inhibits radiation-induced NF kappa B activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol Ther (2002) 1.47
Surgical excision versus curettage plus cryosurgery in the treatment of basal cell carcinoma. Dermatol Surg (2007) 1.47
Rectal cancer: review with emphasis on MR imaging. Radiology (2004) 1.47
Current perspectives on preoperative integrated treatments for locally advanced rectal cancer: a review of agreement and controversies. Oncology (Williston Park) (2012) 1.46
International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys (2010) 1.44
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.43
PET-based treatment planning in radiotherapy: a new standard? J Nucl Med (2007) 1.42
ACR appropriateness Criteria® pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q (2011) 1.42
[Fournier gangrene. A retrospective study of 41 cases]. Cir Esp (2010) 1.41
Magnetic resonance imaging-based monitoring of collateral artery development in patients with intermittent claudication during supervised exercise therapy. J Vasc Surg (2013) 1.39
[Body packer: review and experience in a referral hospital]. Cir Esp (2007) 1.39
Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol (2011) 1.38
An external evaluation of a peer-run "unsanctioned" syringe exchange program. J Urban Health (2003) 1.38
[Surgery in complicated colorectal cancer]. Cir Esp (2006) 1.38
Respiration-induced movement of the upper abdominal organs: a pitfall for the three-dimensional conformal radiation treatment of pancreatic cancer. Radiother Oncol (2003) 1.38
Gastric cancer. J Natl Compr Canc Netw (2010) 1.35
Preoperative estimation of the pathological breast tumour size by physical examination, mammography and ultrasound: a prospective study on 105 invasive tumours. Eur J Radiol (2003) 1.35
Liver volumetry plug and play: do it yourself with ImageJ. World J Surg (2007) 1.34
Intraoperative radiotherapy in colorectal cancer: systematic review and meta-analysis of techniques, long-term outcomes, and complications. Surg Oncol (2012) 1.33
Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 1.31
Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology (2013) 1.31
Management of large vestibular schwannoma. Part I. Planned subtotal resection followed by Gamma Knife surgery: radiological and clinical aspects. J Neurosurg (2011) 1.29
PDCD4 nuclear loss inversely correlates with miR-21 levels in colon carcinogenesis. Virchows Arch (2011) 1.28
Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol (2005) 1.28